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Abstract 
Background: Huangqi decoction (HQD) is used for liver fibrosis and cirrhosis treatment in Chinese medicine. This 
study aims to investigate the pharmacological actions of HQD against liver fibrosis in rats by high‑throughput gene 
expression profiling, network analysis and real‑time qRT‑PCR.
Methods: We analyzed the profiles of differentially expressed genes (DEGs) in dimethylnitrosamine (DMN)‑induced 
liver fibrosis in rat. The liver tissue samples of control group (n = 3), model group (n = 3) and HQD group (n = 3) were 
examined by microarrays. Pathways were analyzed by KEGG. Pathway‑gene and protein–protein interaction (PPI) 
networks were constructed with Cytoscape software. The expression of candidate genes was verified by qRT‑PCR. P 
values less than 0.05 indicated statistical significance.
Results: Collagen deposition and hydroxyproline (Hyp) content were decreased in the HQD group compared with 
the model group (P < 0.001), while that of Hyp in the model group were increased compared with the control group 
(P < 0.001). In comparison with the model group, 1085 DEGs (all P < 0.05, |fold change| >1.5) and 52 pathways in the 
HQD group were identified. TGF‑beta, ECM‑receptor interaction, and the cell adhesion molecules pathways were 
significantly recovered by HQD (P < 0.001). A pathway‑gene network was constructed, including 303 DEGs and 52 
pathways, and 514 nodes and 2602 edges, among 142 genes with node degrees greater than 10. The expressions of 
PDGFra, PDGFrb, PDGFb, PDGFd, COL1A1, COL1A2, COL5A2, and THBS1 were significantly down‑regulated by HQD 
(P < 0.001).
Conclusion: HQD down‑regulated the expressions of PDGFra, PDGFrb, PDGFb, PDGFd, COL1A1, COL1A2, COL5A2 
and THBS1, and TGF‑β and PDGF signaling pathways in the DMN‑induced liver fibrosis in rats.
© 2015 Zhang et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Liver fibrosis and cirrhosis were found associated with 
sustained wound-healing responses to chronic liver 
injury caused by viral, autoimmune, drug-induced, chole-
static, alcoholic, or metabolic pathogenesis [1]. However, 
the matrix components of scar tissue in cirrhosis with 
different etiologies were similar [2]. As the extracellular 
matrix (ECM) undergoes continuous remodeling, with 
the production and degradation of ECM tissues [1, 3], 
initial fibrosis was considered reversible, although some 
previous studies did not support this view [1, 2]. Moreo-
ver, fibrosis stage information not only indicates cirrhosis 
development but also evaluates treatment response [4]. 
Despite the high incidence of hepatic fibrosis worldwide, 
there is currently no validated anti-fibrogenic therapy.
In Chinese medicine (CM), a formula targets many 
molecules in the cells to exhibit therapeutic efficacy and 
reduce adverse effects [5–7]. Huangqi decoction (HQD) 
is one of the several CM formulae that can improve liver 
function and quality of life in patients with liver disorders 
[6, 7]. HQD consists of two medicinal herbs, Radix Astra-
gali (Huang Qi) and Radix et Rhizoma Glycyrrhizae (Gan 
Cao), mixed in a 6:1 (w/w) ratio [8]. In laboratory studies 
on rats, HQD exerted significant therapeutic effects on 
liver fibrosis or cirrhosis induced by dimethylnitrosamine 
(DMN) [8, 9] and bile duct ligation [10].
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Microarray analysis can identify potential disease 
biomarkers [11, 12]. Network-based analyses like net-
work pharmacology can systematically reveal complex 
biological relationships [13–15]. As there are complex 
interactions among multiple compounds, targets, and 
signal pathways, gene expression profiling [16] and net-
work pharmacological methods [17] reveal some phar-
macological actions of CM formulae. Microarray-based 
network analysis can be used to identify potential drug 
targets and biomarkers [18] and reveal some mechanisms 
of CM formulae [19]. This study aims to investigate the 
pharmacological actions of HQD against liver fibrosis in 




DMN was purchased from Sigma-Aldrich (St. Louis, MO, 
USA). R. Astragali (30 g) and R. Glycyrrhizae (5 g), were 
provided by Shanghai Huayu Herbs Co. Ltd. (Shanghai, 
China). The herbs of HQD were accredited by pharma-
cologists and High Performance Liquid Chromatogra-
phy (HPLC) as previously reported [10], and prepared by 
Shanghai Shuguang Hospital. The preparation of aque-
ous extracts of the herbs and quality control were carried 
out as described previously [8–10]. The medicinal herb 
mixture was extracted in boiling water, and the aqueous 
extracts were vacuum-dried at 60 °C to obtain a powder, 
and then stored at −20 °C. The extract was prepared by 
a standardized process and strict quality control accord-
ing to the guidelines of the Chinese State Food and Drug 
Administration [9].
Animal experiments
Similar to previous studies [8, 9], 40 male Wistar rats 
(180–200 g) were housed in standard animal conditions 
with controlled temperature (17–25  °C), humidity (45–
60 %), and a 12-h/12-h light/dark cycle. They were arbi-
trarily allocated into two groups: a control group (n = 10) 
and a DMN-treated group (n = 30). DMN was adminis-
tered intraperitoneally at 10 mg/kg for 3 consecutive days 
each week for 4 weeks in the DMN-treated group; con-
trol rats received equal quantities of physiological saline 
in the same way. At the end of the second week, three 
and six rats from the control and DMN-treated groups, 
respectively, were dissected for fibrosis development 
assessment. The remaining DMN-treated rats were fur-
ther arbitrarily allocated into two groups: a model group 
with saline treatment (n  =  12) and an HQD-treated 
group (n  =  12). In addition to continuous DMN treat-
ment, the rats received daily administration of saline or 
HQD given intragastrically at 1 mL/100 g. At the end of 
the fourth week, all rats were sacrificed and liver tissue 
samples were collected. All procedures were carried out 
in accordance with the “Regulations for the administra-
tion of affairs concerning experimental animals,” pub-
lished in 1988 by the State Scientific and Technological 
Commission [20]. Shanghai University of Traditional 
Chinese Medicine’s Animal Ethics Committee approved 
this study protocol (No. 2011009, Additional file 1) before 
its conduct.
Histological evaluation and hepatic hydroxyproline (Hyp) 
assay
Liver specimens were preserved in 4  % paraformalde-
hyde, dehydrated in a graded alcohol series, embedded in 
paraffin blocks, sectioned to 5-μm-thick slices, placed on 
glass slides, and stained with H&E and Sirius Red. Fibro-
sis scores were determined after examination of three 
different areas of the tissue slide from each rat. Fibrosis 
was graded according to Scheuer’s method [21] as fol-
lows: grade 0, normal liver; grade 1, increased collagen 
without formation of septa (small satellite expansion of 
portal fields); grade 2, formation of incomplete noninter-
connecting septa, from portal tract to central vein; grade 
3, complete but thin interconnecting septa, dividing the 
parenchyma into separate fragments; and grade 4, com-
plete cirrhosis, similar to grade 3 but with thicker septa.
Liver tissues (100 mg) were prepared for Hyp determi-
nation according to Jamall et  al. [22], using a Hydroxy-
proline kit (Nanjing Jiancheng Bioengineering Institute, 
Nanjing, China). Hyp liver content expressed as μg/g wet 
weight, indirectly indicated the tissue collagen content.
cDNA microarray detection and data analysis
Total RNA was extracted by TRIzol Reagent (Invitro-
gen, Carlsbad, CA, USA) following the manufacturer’s 
instructions and checked for a RIN number to inspect 
RNA integration by an Agilent Bioanalyzer 2100. Quali-
fied total RNA was purified by the RNeasy mini kit and 
RNase-Free DNase Set (QIAGEN, GmBH, Germany). 
Total RNA was amplified and labeled by the Low Input 
Quick Amp Labeling Kit, One-Color (Agilent Tech-
nologies, Santa Clara, USA), under the manufacturer’s 
instructions. Labeled cRNA was purified by the RNeasy 
mini kit. Each slide was hybridized with 1.65 μg of Cy3-
labeled cRNA by a Gene Expression Hybridization Kit 
(Agilent technologies, Santa Clara, CA, US) in a hybridi-
zation oven, according to the manufacturer’s instruc-
tions. After 17 h of hybridization, slides were washed in 
staining dishes (Thermo Shandon, Waltham, USA) with 
a Gene Expression Wash Buffer Kit (Agilent Technolo-
gies), under the manufacturer’s instructions. Slides were 
scanned by an Agilent Microarray Scanner G2565BA 
(Agilent Technologies) with default settings, Dye chan-
nel: Green, Scan resolution = 5 μm, PMT 100 %, 10 %, 
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16 bit. Raw data were normalized by Gene Spring Soft-
ware 11.0 (Agilent Technologies). The differences among 
samples, including DEG, hierarchical clustering, Gene 
Ontology (Go), and signalling pathways were calcu-
lated by the SAS system (Shanghai Biochip, Shanghai, 
China). Based on the data of protein–protein interac-
tions from the HPRD [23] and STRING [24] databases, 
pathway-gene and gene PPI networks were constructed 
by Cytoscape 2.8.3 (http://www.cytoscape.org) [25], and 
R2 of PPI networks was also constructed by Cytoscape, 
which represents part of how much information can be 
explained by the independent variables in the dependent 
variable.
Quantitative real‑time polymerase chain reaction 
(qRT‑PCR) analysis
Total RNA was converted to cDNA by the Moloney 
murine leukemia virus (M-MLV, Life, USA) for 1  h 
at 37  °C. We used oligonucleotide primer pairs (SBS 
Genetech Co., Ltd, Shanghai, China.) selected and tested 
for their specificity, including PDGFra, PDGFrb, PDGFb, 
PDGFd, COL1A1, COL1A2, COL5A2, ITGA5, THBS1, 
and IL1R1 mRNAs (Table  1), and carried out a qRT-
PCR analysis by a SYBR green chemistry kit (TOYOBO, 
Osaka, Japan). Each experiment was performed in trip-
licate with β-actin as an endogenous control. Each gene 
was quantified relative to the calibrator. The PCR pro-
gram consisted of an initial period of 10 min at 95 °C fol-
lowed by 40 thermal cycles, each of 10 s at 95 °C, 5 s at 
65  °C, and 30  s at 70  °C by an ABI 9600 real-time PCR 
system (ABI, USA). The data obtained were analyzed 
by the 2−∆∆CT method, and were normalized according 
to the β-actin expression level. Melting curves for each 
PCR reaction were generated to ensure the purity of the 
amplification products.
Statistical analysis
The result was expressed as mean ±  standard deviation 
(SD). Statistical analysis was performed by SPSS software 
(SPSS, Chicago, USA). The statistical significance of dif-
ferences between two groups was analyzed by the Stu-
dent’s unpaired t test or among multiple groups by the 
one-way analysis of variance (ANOVA), followed by LDS 




H&E stain showed no morphological abnormality in the 
control rats (Fig. 1). Persistent reduction of hepatocytes, 
gradual proliferation of cholangiocytes, and continuous 
infiltration of neutrophils were noted in the DMN model 
group. These observation indices were better in the 
HQD- treated group compared with the model group. 
The Sirius Red staining results showed that in the control 
group, there was little collagen except around the small 
central venous walls. In the model group at 4 weeks, col-
lagen was stretched from the portal area to lobular areas, 
and incomplete septa were also observed. Cirrhotic nod-
ules had formed in the model group; by comparison, 
collagen deposition had decreased in the HQD-treated 
group (Fig. 1). Liver Hyp content and changes in the col-
lagen hyperplasia are shown in Table 2. After 4 weeks of 
DMN injection, the model group rats’ liver Hyp content 
increased significantly (P < 0.001) and was 2.47 times as 
much as that in the control group; the degree of collagen 
hyperplasia in the model group was mainly concentrated 
in stages III and IV. Compared with the model group, 
Hyp content in the HQD-treated group decreased sig-
nificantly (P < 0.001) and was 0.43 times as much as that 
in the control group; the degree of collagen hyperplasia 
Table 1 Primer sequences for RT-PCR
Gene Description Primer sequences
Forward Reverse
PDGFra Platelet derived growth factor receptor, alpha polypeptide GAAGGTGGTTGAAGGAACAGC AGGCTCCCAGCAAGTTTACAA
PDGFrb Platelet derived growth factor receptor, beta polypeptide CGCGTGCGTCTGTTTTCAATTT GCGTGGGCTGTGGAATTTCTAA
PDGFb Platelet derived growth factor beta polypeptide GGCCTTCTTAAAGATTGGCTTCT GCCTCATAGACCGCACCAAC
PDGFd platelet derived growth factor D CCCATTCGGAGGAAGAGAAG ATCAGGAAGTTGGCGGACG
COL1A1 Collagen, type I, alpha 1 ACGTCCTGGTGAAGTTGGTC ACCAGGGAAGCCTCTCTCTC
COL1A2 Collagen, type I, alpha 2 GGAGGGAACGGTCCACGAT GAGTCCGCGTATCCACAA
COL5A2 Collagen, type V, alpha 2 GGAAATGTGGGCAAGACTGT TTGATGGTGGTGCTCATTGT
THBS1 Thrombospondin 1 AACGTGGATCAGAGGGACAC GTCATCGTCATGGTCACAGG
ITGA5 Integrin, alpha 5 (fibronectin receptor, alpha polypeptide) GTCGGGGGCTTCAACTTAGAC CCTGGCTGGCTGGTATTAGC
IL1R1 Interleukin 1 receptor, type I AGAGGAAAACAAACCCACAAGG CTGGCCGGTGACATTACAGAT
β‑actin Actin, beta TCCTGTGGCATCCACGAAACT GAAGCATTTGCGGTGGACGAT
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in the model group was mainly concentrated in stages II 
and III.
Gene expression data analysis
We identified differentially expressed genes (DEGs) in the 
microarray data, followed by pathway enrichment analy-
sis. We profiled genome-wide gene expression for six 
liver fibrosis rats (three rats in the model and three in the 
HQD-treated group). Compared with the model group, 
the expression of 1085 genes in the HQD-treated group 
was significantly changed (all P < 0.05, fold change >1.5 
or <0.67); among them, 518 genes were up-regulated and 
567 were down-regulated (Fig. 2a). Pathway enrichment 
analysis of 1085 DEGs showed that these genes were sig-
nificantly enhanced in 52 pathways (all P < 0.05; Fig. 2b).
The TGF-beta signaling pathway was enhanced by 8 
DEGs (Table  3); TGF-beta was involved in liver fibro-
sis [26]. The ECM-receptor interaction pathway, the cell 
adhesion molecules (CAMs) pathway, and the focal adhe-
sion pathway were involved in the development of fibro-
sis lesions [27, 28].
Pathway‑gene network analysis
We constructed a pathway-gene network based on 52 
enrichment pathway-related genes by Cytoscape 2.8.3 to 
identify key genes in the pathway. The pathway-gene net-
work contained 355 nodes and 562 edges, including 303 
genes and 52 pathways (Fig. 3).
Protein–protein interaction (PPI) network analysis
We constructed a DEG PPI network (Fig.  4a) by 
Cytoscape 2.8.3, to find key points (i.e., the main poten-
tial drug targets). The DEG PPI network contained 514 
nodes and 2602 edges, including 142 genes with node 
degree >10. The DEG PPI network centralization and 
heterogeneity were 0.115 and 1.502, respectively. As most 
biological networks are scale-free, the node degrees fol-
low the power law distribution rather than the Poisson 
distribution [29], we also tested whether the MI network 
was scale-free like other biological networks. The node 
degree distribution of the two PPI networks (R2 = 0.796, 
P < 0.001), indicating that the PPI network was scale-free 
(Fig. 4b).
Fig. 1 Effects of HQD on histological changes. N, control group; M, model staining (original magnification ×100)
Table 2 Effects of HQD on fibrotic grades and Hyp content
Grade 0 normal, grade 1 very slight, grade 2 slight, grade 3 moderate, grade 4 severe. Data are expressed as numbers of animals with specific fibrotic grades
** P < 0.01, vs. model group
Group n Hyp content  
(μg/g wet liver)
Fibrotic grade
0 I II III IV
Control 9 181.78 ± 43.45** 9 0 0 0 0
Model 9 427.90 ± 129.46 0 0 1 5 3
HQD‑treated 9 245.86 ± 40.85** 0 1 5 3 0
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Fig. 2 Hierarchical clustering and pathway enrichment of DEGs (n = 3). a DEGs of three HQD‑treated vs. three DMN‑treated rats; an unsupervised 
hierarchical clustering of DEGs between HQD‑treated and DMN‑treated rats showing significantly differential expression revealed two distinct 
clusters. b Fifty‑two enriched pathways based on DEGs showing a difference between HQD‑treated and DMN‑treated rats (P < 0.05). Red nodes 
represent genes, blue nodes represent pathways, and larger circles represent higher degrees
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Degree and betweenness were analyzed for the net-
works to specify the importance of a certain node and 
how this node influences the communication between 
the other two nodes. The degree of a node (biomolecule) 
is the number of targets that the drug has (respectively 
the number of drugs targeting the protein). The between-
ness of a node is defined as the ratio of the number of 
shortest paths passing through a node to the total num-
ber of paths passing through the node [30].
Validation of microarray results by qRT‑PCR analysis
The microarray results were verified by a qRT-PCR analy-
sis using the identical RNA samples. Ten DEGs including 
PDGFra, PDGFrb, PDGFb, PDGFd, COL1A1, COL1A2, 
COL5A2, ITGA5, THBS1 and IL1R1, closely related to 
liver fibrosis, were chosen for the real-time qRT-PCR 
analysis. Compared with the control group, PDGFra, 
PDGFrb, PDGFb, PDGFd, COL1A1, COL1A2, COL5A2 
and THBS1 had significantly increased (P < 0.001) in the 
model group; however, IL1R1 had significantly decreased 
(P  <  0.001). Compared with the model group, PDG-
Frb, COL1A1, and COL1A2 had significantly decreased 
(P  <  0.001) in the HQD-treated group and PDGFra, 
PDGFb, PDGFd, COL5A2, and THBS1 had significantly 
decreased (P < 0.001), but there was no significant differ-
ence for IL1R1 and ITGA5. The results of the qRT-PCR 
analysis for these selected genes were consistent with 
that obtained from microarray data, although the fold 
changes in the expression level differed.
Discussion
HQD has been used to treat consumptive diseases, restless-
ness, hydrodipsia, anorexia, and chronic liver diseases [3, 4]. 
In the present study, HQD alleviated liver fibrosis induced 
by DMN. Both Sirius Red staining and H&E staining results 
demonstrated a significant anti-fibrotic effect of HQD, con-
firmed by liver Hyp content, which was consistent with the 
anti-fibrotic effect of HQD in previous research [3, 31].
Recent research has focused increasingly on investi-
gating drug efficacy by high-throughput technologies 
and network analysis [32–34]. Liver fibrosis develop-
ment is associated with a network of profibrogenic and 
inflammatory signaling pathways [1]. In this study, we 
found that 518 up-regulated genes, 569 down-regulated 
genes, and 52 signaling pathways were regulated by HQD 
treatment, indicating that HQD ameliorated liver fibrosis 
lesions through regulating multiple genes and multiple 
signal pathways.
Highly connected hubs in protein interaction networks 
are potential drug targets [35]. The highly connected 
hubs of both pathway-gene and PPI networks revealed 
10 high degree genes (Table 4), and the levels of PDGFra, 
PDGFrb, PDGFb, PDGFd, COL1A1, COL1A2, COL5A2 
and THBS1 expressions were significantly down-regu-
lated by HQD treatment (Fig.  5), suggesting that these 
genes might be the potential molecular targets of HQD 
against liver fibrosis.
Among the 52 enriched pathways, the TGF-β signaling 
pathway was the most prominent direct inducer of colla-
gen transcription in HSC [36]. THSP1 is a complex mul-
tifunctional protein released from platelet α-granules [37, 
38], and was involved in wound healing and fibrosis [39]. 
The latent TGF-β activation induced by THSP1 could 
prevent liver fibrosis [40]. ITGA5 regulated MMPs gene 
expression during the fibrosis process [41]. Addition-
ally, fibronectin, via ITGA5 receptors, might up-regulate 
MMP-9 gene expression [41].
HSCs produce ECM molecules and release profibro-
genic cytokines, including PDGFs and PDGFrs [42]. 
These cytokines are critical indicators in the pathogenesis 
of hepatic fibrosis [43]. PDGF signaling is one of the best 
characterized pathways of HSC activation [44]. Rapid 
induction of PDGFrb, is followed by development of a 
contractile, fibrogenic phenotype that correlates with the 
degree of fibrosis and inflammation [45]. PDGF induces 
activation of the downstream molecules Erk and Akt in 
activated HSCs, which is associated with cellular prolifer-
ation and migration [46], and transgenic over-expression 
of PDGF leads to liver fibrosis in mice [47]. PDGF action 
is determined by the relative expression of PDGFra and 
PDGFrb on the surface of myofibroblasts [48]. PDGF is 
the potent mitogen for HSCs, and its antagonism could 
be an anti-fibrotic strategy [49]. PDGF receptor tyrosine 
kinase inhibitors might be effective in the treatment of 
Table 3 KEGG pathway annotations of Dif-gene enrichment
KEGG pathway Count Enrichment test P value Gene
TGF‑beta signaling pathway 8 0.0057 THBS1, AMHR2, INHBC, FST, DCN, LTBP1
ECM‑receptor interaction 17 0.00005 ITGA5, COL1A1, THBS1, COL1A2, COL5A2
Cell adhesion molecules 14 0.0005 CLDN4, CLDN9, SELE, CLDN5, VCAM1
Focal adhesion 27 0.00006 ITGA5, THBS1, COL1A2, COL5A2, PDGFrb, PDGFb, PDGFd
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Fig. 3 Pathway‑gene network visualized by Cytoscape. Interaction network analysis of 303 genes. The 303 altered genes were connected in a net‑
work based on signaling pathways. Blue signaling pathway; Red, DEGs. PDGFra, PDGFrb, PDGFb, PDGFd, COL1A1, COL1A2, COL5A2, ITGA5, THBS1, 
and IL1R1 genes had the highest degree values; therefore, they might be important in liver fibrosis pathogenesis
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Fig. 4 DEG PPI network. a PPI network visualized by Cytoscape. Red nodes represent up‑regulated DEGs, green nodes represent down‑regulated 
DEGs, purple nodes represent connect genes, and each edge represents the interaction between them. b The degree of nodes in the PPI network 
followed a power law distribution, indicating that the PPI network is scale‑free
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fibrotic diseases [42]. PDGFs and/or PDGFrs could be the 
target of HQD to slow down the process of liver fibrosis.
COL1A1 expression levels in transdifferentiated epi-
thelial cells were at least one to two orders of magni-
tude lower than that in myofibroblasts [50]. COL1A1, 
COL3A1, COL5A1, and COL5A2 chains were induced 
significantly in active multiple sclerosis lesions and even 
more in inactive lesions. These chains interact to form 
collagen types I, III, and V, which are fibrillar collagens 
[51]. Suppressing COL1A1 and COL1A2 expressions 
might decrease the activation of HSCs and eventually 
prevent liver fibrosis [52].
Treatment with HQD altered the expression of a num-
ber of genes, including different PDGFs and COL1As, 
and also multiple pathways like the TGF-beta and PDGF 
signaling pathways, which would potential targets of 
HQD. Pathway enrichment analysis also showed that 
HQD can affect type 2 diabetes mellitus, hypertrophic 
cardiomyopathy, and other diseases [53]. All the major 
constituents of Astragalus significantly lowered high 
blood glucose levels and body weight and improved 
impaired glucose tolerance in type 2 diabetic models [53, 
54], suggesting that HQD might treat multiple diseases 
through regulating multiple genes and multiple signal 
pathways.
Conclusion
HQD down-regulated the expressions of PDGFra, PDG-
Frb, PDGFb, PDGFd, COL1A1, COL1A2, COL5A2 and 
THBS1, and TGF-β and PDGF signaling pathways in the 
DMN-induced liver fibrosis in rats.
Table 4 Foldchange and degree of Dif-gene
a Fold change referred to an average ratio for only these cases (frequency) in 
which the ratio of change (HQD-treated/DMN-treated) was over 1.5-fold. +, 
up-regulation; −, down-regulation, P < 0.05




PDGFra −1.56 9 7
PDGFrb −1.61 9 7
PDGFb −1.62 8 17
PDGFd −1.92 6 4
COL1A1 −1.77 2 24
COL1A2 −1.54 2 20




Fig. 5 Validation of microarray data by qRT‑PCR analysis (n = 9). Results were expressed as the relative quantification normalized to β‑actin mRNA 
expression. ▲▲P < 0.01 vs. normal group; *P < 0.05, **P < 0.01 vs. model group
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